<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647033</url>
  </required_header>
  <id_info>
    <org_study_id>2015/00644</org_study_id>
    <nct_id>NCT03647033</nct_id>
  </id_info>
  <brief_title>Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent</brief_title>
  <official_title>Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent Implantation in Primary Angle Closure and Primary Angle Closure Glaucoma: Randomized Double-masked Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khoo Teck Puat Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khoo Teck Puat Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the safety and efficacy of a micro-bypass stent in combination with cataract
      surgery in subjects with primary angle closure. Subjects are randomized into two arms:
      phacoemulsification cataract surgery alone versus phacoemulsification cataract surgery
      combined with the micro-bypass stent implantation. Post surgery intraocular eye pressure will
      be recorded to assess the efficacy of both arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To assess the safety and efficacy of the iStent trabecular micro-bypass stent (Glaukos
      Corporation, Laguna Hills, CA) in combination with cataract surgery in subjects with primary
      angle closure and mild to moderate primary angle closure glaucoma

      Method: Prospective, randomised controlled trial, blinded to patient and intra-ocular
      pressure measuring staff. 32 patients, 1:1 ratio, in 2 arms of phacoemulsification alone
      compared to phacoemulsification with iStent.

      Hypothesis: Phacoemulsification with micro-bypass stent has a better intraocular pressure
      (IOP) lowering effect compared to phacoemulsification alone in primary angle closure and
      primary angle closure glaucoma at 1 year after surgery.

      Importance: Primary angle closure and primary angle closure glaucoma are conventionally
      treated with eye drops that lower the intraocular pressure (IOP). Phacoemulsification/lens
      extraction can often help lower the eye pressure by widening the drainage angle and via
      ultrasound mechanisms, however, in some cases the IOP is not lowered, or even can cause the
      IOP to be higher. The iStent implant can be used together with phacoemulsification to lower
      the IOP and in Primary open angle glaucoma, it gives an additional 20% IOP reduction. It is
      unclear what effect the iStent has in primary angle closure or primary angle closure glaucoma
      as it has never been studied. It is important because primary angle closure glaucoma is much
      more common in the Singaporean Chinese population and the iStent can potentially be used to
      control the IOP instead of conventional eye drops and glaucoma surgery which have their own
      potential adverse effects.

      Potential Benefits: iStent with phacoemulsification may control the IOP better than
      phacoemulsification alone, reduce the need for IOP lowering medication after surgery, and
      prevent the need for glaucoma surgery in the future.

      Potential Risks: The iStent has risks of IOP spikes, bleeding in the anterior chamber and
      iStent dislocation.Phacoemulsification has the risks of: infection, bleeding, reduced vision,
      inflammation, posterior capsular rupture, vitreous loss, retinal detachment, endophthalmitis,
      suprachoroidal haemorrhage and Intraocular Lens dislocation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2015</start_date>
  <completion_date type="Actual">August 12, 2017</completion_date>
  <primary_completion_date type="Actual">August 12, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single centre, randomised prospective trial, the patient and the intraocular pressure (IOP)checking staff will be blinded. Randomised by random envelope shuffle technique.
1:1 ratio allocation 2 arms: phacoemulsification alone and phacoemulsification and iStent. 16 patients in each arm, 32 patients in total. The post-operative management is the same for both arms After operation the patient will be followed up at day 1, week 1, week 2, months 1, 3, 6 and 12.
At each visit the patient will have the following tests: Tonometry (IOP check) - Not to be taken by the operating surgeon, to be taken by 2 people, one IOP checker and one reader.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Shuffled envelope system. Patient will be blinded to the procedure. The intraocular pressure (IOP) measure and reader will be blinded to the procedure.
There will be no planned breaking of randomization. Unplanned breaking will happen if any envelopes are damaged or lost. Unmasking will take place after 1 year post operation by the study team to inform the patient of the procedure.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intraocular Pressure Between Baseline and 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>change in mean unmedicated intraocular pressure between baseline and 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glaucoma Medications</measure>
    <time_frame>1 year</time_frame>
    <description>change in number of topical glaucoma medications at 1 year post operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Primary Angle-Closure Glaucoma</condition>
  <condition>Primary Angle Closure Without Glaucoma Damage</condition>
  <arm_group>
    <arm_group_label>phacoemulsification alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>routine phacoemulsification cataract surgery with intraocular lens implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phacoemulsification and iStent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent implantation</intervention_name>
    <description>The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.</description>
    <arm_group_label>phacoemulsification and iStent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  able to provide informed consent

          -  Previous diagnosis of Primary Angle Closure or Primary Angle Closure Glaucoma

          -  Intraocular Pressure above 21mmHg at 3 separate visits

          -  On 1 or more hypotensive medications

          -  Pre-operative visual acuity of no better than 6/12

        Exclusion Criteria:

          -  Other glaucoma diagnosis: Primary Open Angle Glaucoma, secondary glaucoma

          -  Peripheral Anterior Synechiae in the nasal and inferior quadrant

          -  Cloudy cornea affecting view for iStent implantation

          -  Previous glaucoma surgery

          -  History of Ocular trauma

          -  Ocular surface disease

          -  Pre-proliferative or proliferative diabetic retinopathy

          -  Age related macular degeneration with macular scar or macular atrophy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philemon Huang, MMed, FAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Healthcare Group, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Khoo Teck Puat Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>768828</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Craven ER, Katz LJ, Wells JM, Giamporcaro JE; iStent Study Group. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012 Aug;38(8):1339-45. doi: 10.1016/j.jcrs.2012.03.025.</citation>
    <PMID>22814041</PMID>
  </reference>
  <reference>
    <citation>Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial. J Cataract Refract Surg. 2010 Mar;36(3):407-12. doi: 10.1016/j.jcrs.2009.10.031.</citation>
    <PMID>20202537</PMID>
  </reference>
  <reference>
    <citation>Malvankar-Mehta MS, Iordanous Y, Chen YN, Wang WW, Patel SS, Costella J, Hutnik CM. iStent with Phacoemulsification versus Phacoemulsification Alone for Patients with Glaucoma and Cataract: A Meta-Analysis. PLoS One. 2015 Jul 6;10(7):e0131770. doi: 10.1371/journal.pone.0131770. eCollection 2015.</citation>
    <PMID>26147908</PMID>
  </reference>
  <reference>
    <citation>Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE; US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011 Mar;118(3):459-67. doi: 10.1016/j.ophtha.2010.07.007. Epub 2010 Sep 15.</citation>
    <PMID>20828829</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <results_first_submitted>September 5, 2018</results_first_submitted>
  <results_first_submitted_qc>September 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2018</results_first_posted>
  <last_update_submitted>October 3, 2018</last_update_submitted>
  <last_update_submitted_qc>October 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>istent</keyword>
  <keyword>primary angle closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03647033/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03647033/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phacoemulsification Alone</title>
          <description>routine phacoemulsification cataract surgery with intraocular lens implantation</description>
        </group>
        <group group_id="P2">
          <title>Phacoemulsification and iStent</title>
          <description>phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
iStent implantation: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phacoemulsification Alone</title>
          <description>routine phacoemulsification cataract surgery with intraocular lens implantation</description>
        </group>
        <group group_id="B2">
          <title>Phacoemulsification and iStent</title>
          <description>phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
iStent implantation: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="64.3" upper_limit="76.8"/>
                    <measurement group_id="B2" value="65" lower_limit="62" upper_limit="67"/>
                    <measurement group_id="B3" value="67" lower_limit="63" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intraocular Pressure Between Baseline and 1 Year</title>
        <description>change in mean unmedicated intraocular pressure between baseline and 1 year</description>
        <time_frame>1 year</time_frame>
        <population>intraocular pressure of participants measured in mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>Phacoemulsification Alone</title>
            <description>routine phacoemulsification cataract surgery with intraocular lens implantation</description>
          </group>
          <group group_id="O2">
            <title>Phacoemulsification and iStent</title>
            <description>phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
iStent implantation: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure Between Baseline and 1 Year</title>
          <description>change in mean unmedicated intraocular pressure between baseline and 1 year</description>
          <population>intraocular pressure of participants measured in mmHg</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="2.5"/>
                    <measurement group_id="O2" value="14.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glaucoma Medications</title>
        <description>change in number of topical glaucoma medications at 1 year post operation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phacoemulsification Alone</title>
            <description>routine phacoemulsification cataract surgery with intraocular lens implantation</description>
          </group>
          <group group_id="O2">
            <title>Phacoemulsification and iStent</title>
            <description>phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
iStent implantation: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glaucoma Medications</title>
          <description>change in number of topical glaucoma medications at 1 year post operation</description>
          <units>number of glaucoma medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="1.0"/>
                    <measurement group_id="O2" value="0.25" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phacoemulsification Alone</title>
          <description>routine phacoemulsification cataract surgery with intraocular lens implantation</description>
        </group>
        <group group_id="E2">
          <title>Phacoemulsification and iStent</title>
          <description>phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
iStent implantation: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>hyphema</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>intraoperative hyphema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>intraoperative iris prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>intraoperative iris trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>intraoperative iridodialysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Chen</name_or_title>
      <organization>National University Hospital</organization>
      <phone>+6594550281</phone>
      <email>david_chen@nuhs.edu.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

